Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin(SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation

作     者：Wenqian Yang Zimeng Yang Jieru Liu Dan Liu Yongjun Wang 

作者机构：Wuya College of InnovationShenyang Pharmaceutical UniversityShenyang 110016China Key Laboratory of Structure-Based Drugs Design&Discovery of Ministry of EducationShenyang Pharmaceutical UniversityShenyang 110016China 

出 版 物：《Asian Journal of Pharmaceutical Sciences》 (亚洲药物制剂科学（英文）)

年 卷 期：2019年第14卷第6期

页      面：687-697页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Irinotecan Liposome UPLC-MS-MS SPE Pharmacokinetics Bio-distribution 

摘      要：In 2015,liposomal formulation of irinotecan(ONIVYDE)has been approved by FDA and widely applied in the treatment of pancreatic *** is a novel liposome formulation,entrapping CPT-11 in the aqueous core of vesicles using a modified gradient loading *** to toxicity concerns,it is essential to explore a rapid and reliable method to effectively isolate and quantify the non-liposomal,namely,free CPT-11and total CPT-11 in *** study focuses on separation of non-liposomal CPT-11,evaluation of the pharmacokinetics of free CPT-11 and total CPT-11 and bio-distribution after intravenous administration of CPT-11 *** CPT-11 in plasma was separated by solid-phase extraction(SPE).The amount of total CPT-11 and main metabolite 7-ethyl-10-hydroxycamptothecin(SN-38)in plasma was quantified by ultra-performance liquid chromatography–MS/*** calibration curves fitted well and lower limit of quantitation for SN-38,free CPT-11,total CPT-11 and CPT-11 in tissue and were 5 ng/ml,10 ng/ml,4.44 ng/ml and 25 ng/ml *** recoveries,precision and accuracy of the method appear *** this method,the pharmacokinetics and bio-distribution of CPT-11 liposome formulation after an intravenous dose of 2.5 mg/kg were then investigated.